Expert Opinion on Pharmacotherapy

Editorial comment on the manuscript entitled ‘Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction’
pp. 1-2(2)
Author: Petros Perimenis

Oral antiplatelet therapy and percutaneous coronary intervention
pp. 3-12(10)
Authors: Bryan PY Yan; David J Clark; Andrew E Ajani

Maintenance pharmacotherapy of chronic obstructive pulmonary disease: an evidence-based approach
pp. 13-25(13)
Authors: Mark T Dransfield; William C Bailey

Management of hepatitis C virus-related arthritis
pp. 27-34(8)
Authors: Carlo Palazzi; Ignazio Olivieri; Pierluigi Cacciatore; Ernesta Pennese; Emilio D’Amico

Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies
pp. 35-43(9)
Authors: Éric Toussirot; Daniel Wendling

Pharmacotherapy of osteoporosis in men
pp. 45-58(14)
Author: Terrence H Diamond

Novel effects other than antisecretory action and off-label use of proton pump inhibitors
pp. 59-67(9)
Authors: Hidekazu Suzuki; Toshifumi Hibi

Mesalazine for diverticular disease of the colon – a new role for an old drug
pp. 69-74(6)
Author: Antonio Tursi

Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction
pp. 75-84(10)
Author: Sheila A Doggrell

Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck
pp. 85-92(8)
Author: Barbara A Murphy

Role of pantoprazole in the treatment of gastro-oesophageal reflux disease
pp. 93-104(12)
Authors: Frank Serge Lehmann; Christoph Beglinger

Imatinib mesylate in the treatment of gastrointestinal stromal tumour
pp. 105-113(9)
Authors: Dejka M Steinert; John C McAuliffe; Jonathan C Trent

Modafinil: new indications for wake promotion
pp. 115-129(15)
Author: Jonathan RL Schwartz

Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia
pp. 131-139(9)
Authors: Peter P Toth; Michael H Davidson

The European Organisation for Research and Treatment of Cancer: a unique pan-European network
pp. 141-145(5)
Authors: Françoise Meunier

Fluoxetine – do the benefits outweigh the risks in adolescent major depression?
pp. 147-150(4)
Author: Sheila A Doggrell